BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11163147)

  • 1. The von Hippel-Lindau tumor suppressor protein.
    Ivan M; Kaelin WG
    Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
    Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
    J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
    Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW; Ratcliffe PJ
    Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer. Many vessels, faulty gene.
    Kaelin WG
    Nature; 1999 May; 399(6733):203-4. PubMed ID: 10353237
    [No Abstract]   [Full Text] [Related]  

  • 13. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
    Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
    Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VHL takes HIF's breath away.
    Krek W
    Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
    Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The von Hippel-Lindau tumour suppressor protein: new perspectives.
    Ohh M; Kaelin WG
    Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.